Literature DB >> 8537498

Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia.

I Cordone1, L Annino, S Masi, E Pescarmona, S Rahimi, A Ferrari, E Giubilei, P Pignoloni, T Faraggiana, F Mandelli.   

Abstract

AIMS--(1) To assess the diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia (HCL); (2) to compare the immunostaining of bone marrow biopsy specimens with bone marrow and peripheral blood cytospins; (3) to evaluate the sensitivity of the different markers used; (4) to identify the ultrastructural localisation of DBA.44 in HCL variant. METHODS--Immunoenzymatic staining procedures, immunoperoxidase and immunoalkaline phosphatase, were used with a panel of monoclonal antibodies directed to HCL associated antigens. Ultrastructural immunostaining was performed using colloidal gold conjugated antibodies. RESULTS--HCL showed strong cytoplasmic reactivity for CD22, CD25, CD103, DBA.44, kappa, or lambda light chains. Peripheral blood diagnostic hairy cells were found in all the cases with absolute counts ranging from 0.11 x 10(9)/l up to 6.4 x 10(9)/l and values increasing with the size of the spleen. A median of 36.5% of leukaemic cells was found in bone marrow aspirates and 70% in bone marrow trephine specimens. The monoclonal antibodies CD22 and DBA.44 showed the highest and the lowest percentage of positive hairy cells, respectively; this difference was statistically significant (p = 0.0025). Ultrastructural immunolabelling with DBA.44 showed a cytoplasmic membrane localisation of the antigen in one case of HCL variant. CONCLUSIONS--(1) Immunocytochemistry is a useful technique which enhances the accuracy of diagnosis in HCL; (2) peripheral blood immunocytochemistry is recommended because it highlights hairy cells in all cases; (3) CD22 appears to be the most sensitive of the markers tested; (4) ultrastructural analysis is a useful tool in selected cases of HCL variant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8537498      PMCID: PMC502955          DOI: 10.1136/jcp.48.10.955

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

1.  Monoclonal antibodies reactive with hairy cell leukemia.

Authors:  L Visser; A Shaw; J Slupsky; H Vos; S Poppema
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

2.  Production of anti-B monoclonal antibodies (DBB.42, DBA.44, DNA.7, and DND.53) reactive on paraffin-embedded tissues with a new B-lymphoma cell line grafted into athymic nude mice.

Authors:  T al Saati; S Caspar; P Brousset; S Chittal; P Caverivière; H Hounieu; N Dastugue; J B Idoipe; J Icart; C Mazerolles
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

3.  Morphometric analysis of chronic B-cell leukemias--an aid to the classification of lymphoid cell types.

Authors:  D Robinson; P Lackie; V Aber; D Catovsky
Journal:  Leuk Res       Date:  1989       Impact factor: 3.156

Review 4.  Newer purine analogues for the treatment of hairy-cell leukemia.

Authors:  A Saven; L Piro
Journal:  N Engl J Med       Date:  1994-03-10       Impact factor: 91.245

5.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

6.  Hairy cell leukemia preferentially expresses the IgG3-subclass.

Authors:  H C Kluin-Nelemans; M M Krouwels; J H Jansen; K Dijkstra; M J van Tol; G J den Ottolander; E J Dreef; P M Kluin
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

7.  The value of the bone-marrow biopsy in the diagnosis of hairy cell leukemia.

Authors:  J S Burke
Journal:  Am J Clin Pathol       Date:  1978-12       Impact factor: 2.493

8.  A two-color flow cytometry assay for detection of hairy cells using monoclonal antibodies.

Authors:  J S Kristensen; J Ellegaard; P Hokland
Journal:  Blood       Date:  1987-10       Impact factor: 22.113

9.  Hairy cell leukemia: a tumor of pre-plasma cells.

Authors:  K C Anderson; A W Boyd; D C Fisher; D Leslie; S F Schlossman; L M Nadler
Journal:  Blood       Date:  1985-03       Impact factor: 22.113

10.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine.

Authors:  L D Piro; C J Carrera; D A Carson; E Beutler
Journal:  N Engl J Med       Date:  1990-04-19       Impact factor: 91.245

View more
  6 in total

Review 1.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09

Review 2.  Immunoconjugates in the management of hairy cell leukemia.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

Review 3.  Hairy cell leukemia-new genes, new targets.

Authors:  Robert J Kreitman
Journal:  Curr Hematol Malig Rep       Date:  2013-09       Impact factor: 3.952

4.  Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

Authors:  Robert J Kreitman; Maryalice Stetler-Stevenson; Inger Margulies; Pierre Noel; David J P Fitzgerald; Wyndham H Wilson; Ira Pastan
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

Review 5.  Hairy cell leukemia - immunotargets and therapies.

Authors:  Faisal Basheer; David M Bloxham; Mike A Scott; George A Follows
Journal:  Immunotargets Ther       Date:  2014-06-24

Review 6.  Antibody drug conjugate: the "biological missile" for targeted cancer therapy.

Authors:  Zhiwen Fu; Shijun Li; Sifei Han; Chen Shi; Yu Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.